GLOBAL GLP-1 ADHERENCE & SIDE - EFFECT MANAGEMENT MARKET (2026 - 2030)

The GLP-1 Adherence & Side-Effect Management Market was valued at USD 5 Billion in 2025 and is projected to reach a market size of USD 10.06 Billion by the end of 2030. Over the forecast period of 2026-2030, the market is projected to grow at a CAGR of 15%.

As GLP-1 therapies rapidly move from specialist care into everyday clinical practice, ensuring that patients stay on treatment has become as important as prescribing the drug itself. While these therapies have shown strong efficacy in weight management and metabolic health, real-world use is often challenged by side effects, treatment fatigue, and gaps in patient support. The GLP-1 Adherence & Side-Effect Management Market has emerged to address these challenges, bringing together digital health tools, patient education, behavioral coaching, clinical monitoring, and care coordination to help patients remain engaged, manage side effects effectively, and achieve better long-term outcomes. As healthcare systems, employers, and payers increasingly focus on persistence, outcomes, and cost efficiency, this market is becoming a critical layer in the broader GLP-1 treatment ecosystem.

Key Market Insights:

To gain deeper insight into the influence of GLP-1–associated weight loss on the aesthetics industry, with a particular focus on facial aesthetics, a survey was conducted among 174 medical spas, dermatology practices, plastic surgery clinics, and other aesthetic service providers. The results indicate that GLP-1 treatments are broadening and transforming the customer base within the aesthetics market.

As the market continues to evolve, stakeholders must closely monitor emerging trends and shifts in patient and provider preferences, as these factors are likely to shape strategic decisions and market dynamics in the coming years.

The side effects associated with the treatment are restraining market growth.

North America has the biggest share in the GLP-1 Adherence & Side-Effect Management Market.

Market Drivers:

Increasing demand for weight management solutions is contributing to market expansion.

With global obesity rates on the rise, an increasing number of individuals are turning to effective pharmacological solutions. This pattern reflects an evolving consumer mindset toward proactive health management, as GLP-1 adherence and side-effect management solutions are increasingly acknowledged for offering combined benefits in weight reduction and glycemic regulation.

Advancements in drug formulations are contributing to market growth.

Innovations in drug formulations are emerging as a defining feature of the GLP-1 Adherence & Side-Effect Management Market. Pharmaceutical manufacturers are actively investigating diverse delivery approaches, such as extended-release injectable options and oral dosage forms. These developments are designed to improve patient adherence and ease of use, which may contribute to improved clinical outcomes and broader market adoption.

Market Restraints and Challenges:

Glucagon-like peptide-1 (GLP-1) Adherence & Side-Effect Management solutions have gained prominence as effective therapeutic options for obesity and diabetes. In recent years, their transformative potential has been increasingly recognized, particularly for the more than one billion individuals affected by obesity and over 800 million living with diabetes worldwide. However, a clear understanding of associated risks is essential to support evidence-based decision-making. The potential adverse effects linked to GLP-1 Adherence & Side-Effect Management can be broadly classified into well-established reactions, infrequent events with weaker or uncertain causal relationships, and newly emerging or hypothesized effects that remain under investigation.

Market Opportunities:

Increasing awareness and acceptance of GLP-1 therapies are creating new opportunities within the market. There has been a significant rise in awareness and acceptance of GLP-1 therapies among healthcare providers as well as patients. Educational programs and targeted marketing efforts have successfully highlighted the advantages of GLP-1 Adherence & Side-Effect Management, contributing to a better-informed patient base. Consequently, the GLP-1 drug market has witnessed a substantial increase in prescription volumes, with growth exceeding 30% over the past year.

GLOBAL GLP-1 ADHERENCE & SIDE - EFFECT MANAGEMENT MARKET

Market Segmentation:

Segmentation By Product:

• Ozempic
• Mounjaro
• Trulicity
• Rybelsus
• Wegovy
• Victoza
• Saxenda
• Zepbound
• Other Products

The Ozempic segment held a leading position in the GLP-1 Adherence & Side-Effect Management market. Ozempic is a U.S. FDA–approved branded prescription medication indicated for the treatment of adults with type 2 diabetes. The growing prevalence of type 2 diabetes, along with the drug’s strong safety and efficacy profile compared with other GLP-1 adherence and side-effect management options, is driving increased adoption. In March 2024, clinical trial data from Novo Nordisk A/S showed that Ozempic slowed the progression of chronic kidney disease (CKD) and lowered the risk of mortality and cardiovascular events by 24% among patients with diabetes. These findings have encouraged physicians to consider Ozempic as a treatment option for children and adolescents with type 2 diabetes, further supporting its global uptake.

Zepbound is projected to experience substantial growth over the forecast period. This expansion is primarily driven by its global regulatory approvals and strong demand stemming from its high efficacy and favorable tolerability profile. In August 2024, Eli Lilly and Company reached a key supply milestone with the introduction of single-dose vials of Zepbound, one of its leading weight-loss therapies.

By Application:

• Type 2 Diabetes Mellitus
• Obesity

The type 2 diabetes mellitus segment continues to hold a leading position in the GLP-1 Adherence & Side-Effect Management market and is expected to register significant growth at a notable CAGR over the forecast period. This trend is driven by the increasing prevalence of type 2 diabetes and the widespread availability of GLP-1 therapies for its management. According to the World Health Organization (WHO), type 2 diabetes accounts for over 95% of all diabetes cases globally. Traditionally considered an adult-onset or non–insulin-dependent condition, type 2 diabetes is now increasingly observed in children due to shifts in dietary patterns. Currently, several GLP-1 therapies, including Dulaglutide (Trulicity), Exenatide (Byetta), Exenatide extended-release (Bydureon), and Liraglutide (Victoza), are employed to treat patients with type 2 diabetes mellitus. As a result, the rising incidence of this condition is expected to drive further demand for GLP-1 adherence and side-effect management therapies.

The obesity segment is also projected to experience significant growth over the forecast period. This expansion is attributed to the increasing global obese population and the approval of new GLP-1 therapies for obesity treatment. According to a 2024 study by the NCD Risk Factor Collaboration (NCD-RisC), over 880 million adults and 159 million children and adolescents aged 5–19 years worldwide are affected by obesity. High-dose Liraglutide and Semaglutide are currently administered to obese patients following U.S. FDA guidelines, owing to their demonstrated weight-loss effects. Therefore, the introduction and approval of new GLP-1 therapies for obesity management are anticipated to be key drivers of market growth.

By Route of Administration:

• Parenteral
• Oral

The parenteral segment has established itself as the dominant category within the GLP-1 Adherence & Side-Effect Management market.This leadership is largely driven by the broad availability of parenteral GLP-1 agonists for diabetes treatment and their advantages over other administration routes, including higher efficacy. Key parenteral GLP-1 therapies approved for clinical use include Dulaglutide (Trulicity), Exenatide extended-release (Bydureon), Exenatide (Byetta), Semaglutide (Ozempic), Liraglutide (Victoza, Saxenda), Lixisenatide (Adlyxin), and Semaglutide (Rybelsus). The global approval of new parenteral GLP-1 therapies is expected to further support market growth.

The oral administration segment is projected to experience rapid growth during the forecast period. Oral GLP-1 therapies are increasingly recognized for their convenience and effectiveness in managing type 2 diabetes. Currently, Semaglutide (Rybelsus) holds U.S. FDA approval for the treatment of diabetes, highlighting the expanding role of oral GLP-1 therapies in the market.

By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Retail pharmacies continue to hold a leading position in the GLP-1 Adherence & Side-Effect Management market, acting as the main access point for patients seeking treatment for chronic metabolic conditions. Their extensive geographic presence ensures consistent availability of GLP-1 products, helping to meet the growing demand among patients with diabetes and obesity. The support provided by pharmacists enhances patient adherence, particularly for injectable formulations that require proper administration guidance. Additionally, retail pharmacies benefit from established reimbursement frameworks that streamline prescription fulfillment, while high consumer footfall increases prescription conversion rates, further strengthening their market share. Ongoing awareness initiatives and patient counseling services in retail settings also contribute to their leading role in the distribution network.

The online pharmacy segment is expected to experience rapid growth over the forecast period. This expansion is primarily driven by increased internet connectivity and the convenience of purchasing medications and healthcare products online. Patients are increasingly drawn to digital platforms for their accessibility, ease of use, and the ability to obtain prescriptions and over-the-counter treatments from home, often with doorstep delivery. As the prevalence of diabetes continues to rise, the demand for online pharmacy services is anticipated to support significant market growth.

Market Segmentation: Regional Analysis:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

The North American GLP-1 Adherence & Side-Effect Management market is dominated by well-established brands. These therapies have gained widespread acceptance among both patients and healthcare professionals due to their demonstrated benefits in reducing cardiovascular risk, improving glycemic control, and supporting weight loss. The U.S. GLP-1 market accounts for the largest revenue share in North America, driven by the high prevalence of type 2 diabetes, which represents the majority of diabetes cases in the country. The growing severity of the disease, fueled by rising obesity rates and sedentary lifestyles, has increased demand for effective treatments such as GLP-1 therapies. High adoption rates of these medications continue to further propel market growth in the region.

The Asia Pacific GLP-1 Adherence & Side-Effect Management market is expected to experience significant growth over the forecast period. Factors such as the region’s expanding healthcare infrastructure, large target population, and high unmet clinical needs are contributing to this potential. Leading companies, including Novartis AG and Eli Lilly and Company, are actively developing innovative GLP-1 solutions to address diabetes and obesity in the region. In China, the market is projected to grow rapidly, driven by urbanization, changing lifestyles, increasing type 2 diabetes prevalence, and the expansion of healthcare services. Additionally, continuous efforts by key players to develop novel therapeutics are expected to support sustained market growth.

COVID-19 Impact Analysis:

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are hypothesized to provide beneficial effects on COVID-19 outcomes due to their anti-inflammatory properties. In a COVID-19 ward, patients hospitalized with severe interstitial bilateral pneumonia caused by SARS-CoV-2 infection, who also had type 2 diabetes (T2D) or in-hospital hyperglycemia (IHH), received GLP-1 RA therapy alongside standard care as per routine clinical protocols. The primary objective of this study was to assess the association between GLP-1 RA treatment and patient outcomes.

Latest Market News:

In July 2024, Amylyx Pharmaceuticals acquired Avexitide, a GLP-1 adherence and side-effect management therapy, from Eiger Biopharmaceuticals, Inc. Avexitide holds FDA breakthrough therapy designation for the treatment of Postbariatric Hypoglycemia (PBH) and congenital hyperinsulinism. Phase 2 trials indicated significant reductions in severe hypoglycemic events, and the therapy is expected to enter Phase 3 trials for PBH in early 2025.

In February 2024, Eli Lilly and Company announced plans to launch Mounjaro, its established diabetes and obesity treatment, in India, pending regulatory approval. This launch is anticipated to contribute positively to the growth of the Indian GLP-1 market.

Latest Trends and Developments:

The GLP-1 Adherence Market is undergoing a significant transformation, largely driven by the rising prevalence of metabolic disorders, including type 2 diabetes and obesity. This evolution is supported by increasing awareness of the clinical benefits of GLP-1 adherence and side-effect management therapies, which are widely recognized for their effectiveness in glycemic control and weight management. Pharmaceutical companies are actively investing in research and development, focusing on the introduction of novel formulations and innovative delivery methods to enhance patient outcomes.

The integration of digital health technologies into treatment protocols is further improving patient adherence and monitoring, potentially resulting in better therapeutic outcomes. Concurrently, regulatory authorities are adapting to the changing landscape, which may accelerate approvals for innovative GLP-1 therapies. The competitive environment in the GLP-1 drug market is intensifying, with both established companies and new entrants striving to expand their market presence. This trend points toward a future in which personalized medicine may become increasingly important, enabling treatments tailored to individual patient needs.

Key Players in the Market:

Novo Nordisk A/S

boehringer ingelheim

Pfizer Inc.

Eli Lilly and Company

Zealand Pharma

Hanmi Pharmaceutical Co.

AstraZeneca

GlaxoSmithKline plc

Amgen Inc.

Sanofi